Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis.

What It Covers

This meta-analysis looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

However, the same test may be used for measuring QoL, well-being or health status in different studies.

QoL has been defined as the subjective appraisal of one's current life based primarily on psychological function.

Who the Included Studies Covered

By PubMed's age tags, the people studied were adults and middle-aged adults.

Studies were included that evaluated the effect of GH on patient-reported outcomes in adults with GHD (aged 18 years and above).

According to generally accepted definitions the researchers classified the questionnaires as instruments measuring QoL, well-being and health status.

How the Review Was Done

The researchers searched the electronic databases PUBMED and PiCarta from 1985 to 2004.

By means of meta-analyses the average effect size (d) for QoL, well-being and health status was calculated.

What Was Measured

However, the same test may be used for measuring QoL, well-being or health status in different studies.

The most important in the appraisal of well-being is mental function and concerning health status patients evaluate physical function as most important.

The subject headings attached to it are Affect, Health Status, Holistic Health, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism and Psychometrics.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Health and quality of life outcomes), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.